Background. Patients with esophageal carcinoma receiving postoperative chemotherapy showed superior diseasefree survival than those receiving surgery alone in a Japan Clinical Oncology Group trial (JCOG9204). The purpose of this study was to evaluate optimal perioperative timing-that is, before or after surgery-for providing chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Methods. Eligible patients with clinical stage II or III, excluding T4, squamous cell carcinoma were randomized to undergo surgery followed (group 1) or preceded (group 2) by chemotherapy consisting of two courses of cisplatin plus 5-fluorouracil. The primary end point was progression-free survival.
completion of patient accrual. Progression-free survival did not reach the stopping boundary, but overall survival in group 2 was superior to that of group 1 (P = 0.01). Therefore, the Data and Safety Monitoring Committee recommended early publication. Updated analyses showed the 5-year overall survival to be 43% in group 1 and 55% in group 2 (hazard ratio 0.73, 95% confidence interval 0.54-0.99, P = 0.04), where the median follow-up of censored patients was 61.6 months. Concerning operative morbidity, renal dysfunction after surgery in group 2 was slightly higher than in group 1. Conclusions. Preoperative chemotherapy with cisplatin plus 5-fluorouracil can be regarded as standard treatment for patients with stage II/III squamous cell carcinoma.
Esophageal carcinoma is a formidable disease, with possible distant failure even if locoregional disease is controlled successfully by radical surgery. A randomized controlled trial by the Japan Clinical Oncology Group (JCOG9204) comparing postoperative adjuvant chemotherapy with cisplatin plus 5-fluorouracil with surgery alone, showed superior disease-free survival in the postoperative chemotherapy group. 1 In Western countries, preoperative chemoradiotherapy is a standard treatment, but the results of the JCOG9204 study showed far better survival than that of those trials. [2] [3] [4] In addition, locoregional tumor recurrence was observed in less than half of all cases of recurrence in the JCOG9204. We therefore speculated that aggressive esophageal cancer surgery in Japan is one plausible reason for the lower local recurrence rate, and therefore, eradication of systemic micrometastasis by preoperative chemotherapy followed by aggressive surgery may be a more promising strategy than reinforcement of local tumor control by chemoradiotherapy.
Concerning preoperative chemotherapy, a randomized controlled study in the UK demonstrated that preoperative chemotherapy was superior to surgery alone in overall survival in patients with esophageal carcinoma of any cell type. 5, 6 On the other hand, another randomized study in the United States showed no survival benefit for preoperative chemotherapy compared with surgery alone. 7, 8 Therefore, it is still controversial whether preoperative chemotherapy can improve the survival of patients with esophageal squamous cell carcinoma and/or adenocarcinoma compared with surgery alone or postoperative chemotherapy. 9 The objective of this multi-institutional randomized controlled trial was to evaluate the survival benefit of preoperative chemotherapy with cisplatin plus 5-fluorouracil compared with postoperative chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
PATIENTS AND METHODS

Eligibility
The eligibility criteria for entering this study were as follows: histologically proven squamous cell carcinoma of the thoracic esophagus; clinical stage II or III excluding T4 disease (UICC tumor, node, metastasis system [TNM] classification); 10 resectable disease; age 75 years or younger; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; no previous chemo-or radiotherapy for any malignancies; sufficient organ function; and written informed consent. Upper gastrointestinal endoscopy, esophagography, and either computed tomography or magnetic resonance imaging were required, and endoscopic ultrasonography was recommended, for clinical staging. The study protocol was approved by the Protocol Review Committee of JCOG and the institutional review board of each participating institution.
Randomization
After the confirmation of the eligibility criteria, the patients were randomized at the JCOG Data Center into either the postoperative chemotherapy group (group 1) or the preoperative chemotherapy group (group 2). In group 1, surgery was followed by chemotherapy after 2 to 10 weeks, and in group 2, chemotherapy was followed by surgery within 5 weeks. A minimization method was used to balance institution and clinical lymph node status (cN0 vs. cN1).
Surgery
All patients underwent total or subtotal thoracic esophagectomy and regional lymphadenectomy with curative intent. Either right or left thoracotomy was acceptable. Thoracoscopic esophagectomy was acceptable but transhiatal esophagectomy was not. 11 Regional lymph nodes included not only mediastinal (paraesophageal, paratracheal, subcarinal, supradiaphragmatic and posterior mediastinal lymph nodes) but also perigastric nodes. Dissection of distant lymph nodes such as cervical nodes, i.e., a threefield lymphadenectomy, or celiac nodes, was optional. 12 Esophageal reconstruction was performed using the stomach, colon, or jejunum.
Chemotherapy
Chemotherapy with cisplatin plus 5-fluorouracil was repeated twice every 3 weeks in each arm. A dose of 80 mg/m 2 cisplatin was given by intravenous drip infusion for 2 h on day 1; 5-fluorouracil was administered at a dose of 800 mg/m 2 by continuous infusion on days 1 through 5. In patients with node-negative status (pN0) resected specimens in group 1, chemotherapy was not provided postoperatively on the basis of the results of our former study (JCOG9204). In patients whose response to the first course of chemotherapy was progressive disease in group 2, a second course of chemotherapy was not given, in order to take advantage of the probability for curative resection.
Study Design and Statistical Analysis
The primary end point was progression-free survival, as in the preceding study. The secondary end points were overall survival, chemotherapy toxicities, operative morbidity and mortality, response rate in group 2 and complete resection rate. The expected 5-year progression-free survival in group 1 was 50%. This study was designed to randomize 330 patients to detect about 13% improvement in 5-year progression-free survival in group 2 with a onesided alpha error of 0.05 and a power of 0.80. The planned accrual and follow-up period was 4 and 3 years.
Overall survival was measured from the date of randomization to the date of death, or last follow-up. Progression-free survival was measured from the date of randomization to the date of first evidence of relapse or death due to any cause. For patients who had not relapsed or died, progression-free survival was censored at the last date at which the absence of relapse was confirmed. Overall and progression-free survival curves were calculated by the Kaplan-Meier method. Confidence intervals (CI) of survival distribution were based on the Greenwood formula. Stratified Cox regression analysis with clinical lymph node status as a stratification variable was carried out to estimate the hazard ratio in the primary analysis of progression-free survival, and unstratified Cox regression analyses were applied for the other analyses. This study was designed and conducted on the basis of one-sided testing, and the results are presented with two-sided P values. All the statistical analyses were performed with SAS software release 9.1 (SAS Institute, Cary, NC) by the JCOG Data Center. This study was registered with ClinicalTrials.gov, identification number NCT00190554.
Clinicopathologic parameters are expressed according to the TNM Classification of the International Union Against Cancer (UICC). 10 The clinical response was evaluated on the basis of the Response Evaluation Criteria in Solid Tumors. 13 Adverse events were classified according to U.S. National Cancer Institute common toxicity criteria, version 2.0. 14 
RESULTS
Patient Characteristics
Twenty-four leading institutions in Japan participated in this study. During 6 years of May 2000 to May 2006, 330 patients were randomly assigned to either group 1 (166 patients) or group 2 (164 patients). These patients comprised 11% (330 of 3092) of all patients with clinical stage II and III esophageal cancer treated in participating institutions during the study because informed consent was obtained in only 19% (330 of 1716) of all patients who met the eligibility criteria. The characteristics of the two groups were similar (Table 1) .
Disposition of the Patients
The trial profile is shown in Fig. 1 . In group 1, 108 patients were resected completely (R0) and diagnosed as pathologic node positive, among which 81 patients (75%) completed 2 courses of postoperative chemotherapy. Thirty-nine patients were diagnosed as R0 and pN0; therefore, all but 1 of that subset (38 patients) did not undergo postoperative chemotherapy, in compliance with the study protocol. Among 15 patients diagnosed as incomplete resection (R1/R2), 13 underwent subsequent chemotherapy. In group 2, 140 patients (85.4%) completed two courses of preoperative chemotherapy and 154 patients underwent surgery. There was a significant difference between the completion rate of chemotherapy in each group (P = 0.04).
Surgical Treatment
Transthoracic esophagectomy via right thoracotomy was performed in 157 patients in group 1 and in 149 patients in group 2. Left thoracotomy was performed in 1 patient and thoracoscopic esophagectomy in 4 patients in each group. No patient underwent transhiatal esophagectomy without thoracotomy, in compliance with the study protocol. A three-field lymphadenectomy was performed in 103 patients in each group.
Toxicities and Tumor Responses to Chemotherapy
Toxicities of chemotherapy were commonly mild and were observed slightly more frequently in group 1. The incidences of major grade 3 or 4 adverse events in groups 1 
Operative Morbidity and Mortality
Median intraoperative blood loss was 446 ml in group 1 and 450 ml in group 2. In group 2, renal dysfunction after surgery (9 patients, 6%) was slightly more frequent than in group 1 (4 patients, 3%). There were no remarkable differences between two groups in terms of other postoperative complications. One patient in each group died of causes related to surgery (esophagobronchial fistula on the 12th postoperative day in group 1, aortic perforation on the 8th postoperative day in group 2).
Progression-free and Overall Survival
The planned first interim analysis was done in March 2004 at the midpoint of patient accrual and the planned second interim analysis was performed in March 2007 after completion of patient accrual. At the second interim analysis, the information time was 78% (observed/expected number of events = 159/205) and the corresponding threshold for the P value was one-sided 0.02 (two-sided P = 0.04). The primary analysis compared progressionfree survival, and its one-sided stratified log-rank P value was 0.04 (two-sided P value = 0.08). The hazard ratio of group 2 compared with group 1 was 0.76 with multiplicity adjusted 95% (unadjusted 94.9%) CI of 0.56-1.04.
Even though group 2 showed better tendency in progression-free survival, the primary end point progressionfree survival did not meet the prespecified stopping criterion. However, a large difference between two groups was observed in overall survival (P = 0.01, unstratified logrank test; hazard ratio 0. hazard ratio of group 2 to group 1 was 0.73 (95% CI 0.54-0.99, P = 0.04).
We gave some treatments for progression to 72 patients (43%) in group 1 and 76 patients (46%) in group 2. Slightly more underwent a subsequent surgical treatment for progression in group 2 (12 patients, 7%) than group 1 (6 patients, 4%).
Subgroup Analysis
The results of subgroup analyses of overall survival regarding clinical lymph node status, clinical tumor depth, clinical stage, performance status and tumor location are shown in Fig. 4 . The 5-year overall survival was 54.5/ 49.4% (group 2/group 1) in cN0 patients and 55.3/39.5% (group 2/group 1) in cN1 patients. Treatment was more effective in group 2 in clinical stage II cases, cases involving the upper and the middle third of the esophagus, or cases invading less deep layers.
Downstaging and Curability
Data on the distribution of baseline clinical stage, pathologic stage, and surgical curability are shown in Fig. 5 . Although the baseline clinical stages were similar, there were more pathologic stage II or lower cases in group 2 (48%) than group 1 (33%) (P = 0.01). The proportion of patients with cN0 in both groups was almost identical (33% in group 1 and 35% in group 2) (P = 0.64), whereas pN0 was seen in 24% in group 1 and 35% in group 2 (P = 0.05). Stage IV disease due to M1LYM was less frequent in group 2 (12%) than group 1 (19%) (P = 0.09). There were slightly more patients who underwent complete resection (R0) among patients who underwent surgery in group 2 (96%) than in group 1 (91%) (P = 0.04). 15 
DISCUSSION
Our study demonstrated that adjuvant chemotherapy should be induced before surgery rather than after surgery in patients with squamous cell carcinoma of the thoracic esophagus. There are 3 possible reasons for the better preoperative chemotherapy results. First, downstaging was achieved in some patients by preoperative chemotherapy. Although the proportion of the patients with clinical stage II was similar in the 2 groups, the proportion with pathologic stage II or lower stage was higher in group 2. Second, complete resection (R0) was slightly more frequent in group 2 than group 1. Third, the completion of protocol treatment was much better in group 2 than group 1. Treatment according to the protocol with two courses of chemotherapy and R0 resection was done in 85% of group 2 patients, but only in 75% in group 1. These results suggest it is not difficult to perform preoperative chemotherapy in esophageal cancer surgery candidates.
In our previous study (JCOG9204), less than half of all recurrences were locoregional, and therefore, chemoradiotherapy was not chosen as the test treatment arm in this study. Patients with a single locoregional tumor recurrence in this study consisted of 31% of patients with tumor recurrence in group 1 and 25% in group 2. The lower rate of locoregional recurrence in the present study may result from our meticulous surgical procedure. Our standard surgical procedure was transthoracic esophagectomy with regional lymphadenectomy. The results of our study suggest that preoperative chemotherapy is a good treatment strategy if sufficient local tumor control is achieved by aggressive surgical procedures, and improves overall survival for patients with squamous cell carcinoma. On the contrary, if local tumor control is insufficient, more aggressive adjuvant therapy such as preoperative chemoradiotherapy may be a preferable treatment modality. The clinical question of which is better, preoperative chemotherapy or preoperative chemoradiotherapy, still needs to be clarified, and now we are planning the next clinical trial to resolve that question. 16 Numerous reports have been devoted to adjuvant chemotherapy for esophageal cancer especially concerning controversies in terms of optimal timing, or indications according to histologic type. Kelsen et al. reported that preoperative chemotherapy with cisplatin and fluorouracil did not improve overall survival compared with surgery alone. 7, 8 More than half of their cases were adenocarcinoma, and the proportion of R0 resection was only about 60% in each arm. The difference from the results of our study, may allow speculation that preoperative chemotherapy with cisplatin and fluorouracil might be too weak to complement locoregional tumor control if R0 resection is not achieved. On the other hand, the Medical Research Council found that preoperative chemotherapy with the same combination improved survival relative to outcome with surgery alone. In the MRC study, 30% of patients treated with surgery alone underwent incomplete resection, and survival in the group with surgery alone was unusually poor (median, 13 months). 5 Because these two pivotal studies demonstrated completely different conclusions, the benefit of preoperative chemotherapy even limited to patients with esophageal squamous cell carcinoma was controversial before our study, even though a recent metaanalysis showed a benefit of preoperative chemotherapy in patients with adenocarcinoma, but not in patients with squamous cell carcinoma. 17 The subgroup analysis suggested better survival superiority in group 2 depending on the site of tumor location, i.e., better results were obtained in higher esophageal site than in the lower esophagus. The middle third of the esophagus is the most frequent site of esophageal squamous cell carcinoma in Japan and such cases tend to metastasize to not only the lower mediastinal and perigastric nodes but the upper mediastinal and cervical nodes. 18 Therefore, upper mediastinal lymphadenectomy is necessary, but it is less likely to be carried out thoroughly than lower mediastinal and perigastric lymphadenectomy as a result of anatomic limitations. 19 Preoperative chemotherapy could overcome lack of locoregional tumor control by upper mediastinal lymphadenectomy.
One controversy of our study is the protocol treatment in group 1 in which the postoperative chemotherapy is not given to pN0 patients. In our preceding JCOG9204, the disease-free survival showed little difference between the surgery-alone group and the surgery-plus-postoperative chemotherapy group in the pN0 subgroup: 5-year diseasefree survivals were even better in the surgery-alone group (76%) than the postoperative chemotherapy group (70%), hazard ratio of the postoperative chemotherapy group to the surgery-alone group was 0.94 (95% CI 0.35-2.50). When planning the present study, giving chemotherapy after surgery for pN0 patients with comparatively good prognosis was not acceptable in the community considering the benefit/risk ratio and our group members reached an agreement that the standard treatment for pN0 patients should be surgery alone. Such patient selection based on pathologic findings would be one advantage of postoperative chemotherapy especially when clinical nodal status is not necessarily concordant with pathologic status. Furthermore, the 5-year overall survival of pN0 patients undergoing no postoperative chemotherapy in group 1 was not bad (64%), whereas that of pN1 patients who were unable to undergo postoperative chemotherapy in group 1 was dismal (0%). That means the former (i.e., pN0 with no postoperative chemotherapy) was not the main reason for the poor outcome in group 1; rather, it was the latter (i.e., pN1 with no postoperative chemotherapy for the various reasons).
Another controversy of our study is the discrepancy between progression-free survival and overall survival where overall survival showed larger difference than progression-free survival. Longer survival after progression in group 2 is one of the possible explanations for this discrepancy. This may have resulted because more patients in group 2 who underwent a subsequent surgical treatment for progression. Because progression-free survival is not a validated surrogate end point of overall survival, we should have adopted overall survival as the primary end point. Our Data and Safety Monitoring Committee discussed this issue and decided to recommend early publication because of the large difference observed in overall survival by true end point, reflecting a direct patient benefit.
In conclusion, preoperative chemotherapy with cisplatin plus 5-fluorouracil followed by surgery improved overall survival without additional serious adverse events. Preoperative chemotherapy with cisplatin plus 5-fluorouracil can be regarded as a new standard treatment modality for patients with stage II/III esophageal squamous cell carcinoma.
